Predicting how inhaled drugs affect different parts of the lungs using blood data.
Official title: Feasibility of predicting regional lung exposure from systemic pharmacokinetic data of generic OIDPs via population pharmacokinetic modeling and non-compartmental approaches
Funded at University of Florida · NIH-10904773 · Data updated 2026-11-12
This study is looking at how well inhaled medications reach different parts of the lungs by using information from the bloodstream, which could help make sure these treatments are safe and effective, especially for people with asthma, and might lead to more affordable options for everyone.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project start | July 1, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $249,998 |
| NIH project number | 5U01FD007936-02 |
| Project ID | NIH-10904773 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients suffering from chronic respiratory diseases, particularly asthma, who may benefit from improved inhaled medication options.
✕Less likely to help
Patients with non-respiratory conditions or those who do not use inhaled medications may not receive any benefit from this research.
What this research studies
This research investigates how to predict the exposure of inhaled medications in various regions of the lungs by analyzing data from the bloodstream. By using advanced modeling techniques, the study aims to create simulations that can accurately reflect how inhaled drugs behave in the lungs compared to their presence in the blood. This approach could help in assessing the effectiveness and safety of generic inhaled medications, potentially leading to more affordable treatment options for patients with chronic respiratory diseases like asthma.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and affordable inhaled medications for patients with respiratory conditions.
How similar studies have gone: While the approach of using population pharmacokinetic modeling is established, the specific application to predicting lung exposure from systemic data in generic inhaled medications is relatively novel.
Where this research is happening
-
University of Florida
Gainesville, United States Active
Researchers
- Principal investigator: Bulitta, Jurgen Bernd — University of Florida
- Study coordinator: Bulitta, Jurgen Bernd
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.